231 related articles for article (PubMed ID: 28441276)
1. AUGS Consensus Statement: Association of Anticholinergic Medication Use and Cognition in Women With Overactive Bladder.
This document was developed by the American Urogynecologic Society (AUGS) Guidelines Committee with the assistance of Tonya N. Thomas, MD, and Mark D. Walters, MD. This document reflects clinical and scientific advances as of the date issued and is subject to change. The information should not be construed as dictating an exclusive course of treatment or procedure to be followed. Its content is not intended to be a substitute for professional medical judgment, diagnosis, or treatment. The ultimate judgment regarding any specific procedure or treatment is to be made by the physician and patient in light of all circumstances presented by the patient.
Female Pelvic Med Reconstr Surg; 2017; 23(3):177-178. PubMed ID: 28441276
[TBL] [Abstract][Full Text] [Related]
2. Clinical Consensus Statement: Association of Anticholinergic Medication Use and Cognition in Women With Overactive Bladder.
Female Pelvic Med Reconstr Surg; 2021 Feb; 27(2):69-71. PubMed ID: 33497068
[TBL] [Abstract][Full Text] [Related]
3. Characteristics of providers who prescribed only anticholinergic medications for overactive bladder in 2020.
Carr DN; Macharia A; Hacker MR; Winkelman WD
Am J Obstet Gynecol; 2023 Sep; 229(3):316.e1-316.e7. PubMed ID: 37244459
[TBL] [Abstract][Full Text] [Related]
4. The cognitive safety of antimuscarinics in the treatment of overactive bladder.
Araklitis G; Robinson D
Expert Opin Drug Saf; 2020 Oct; 19(10):1303-1313. PubMed ID: 32857638
[TBL] [Abstract][Full Text] [Related]
5. The cognitive effect of anticholinergics for patients with overactive bladder.
Welk B; Richardson K; Panicker JN
Nat Rev Urol; 2021 Nov; 18(11):686-700. PubMed ID: 34429535
[TBL] [Abstract][Full Text] [Related]
6. Cognitive Effects of Anticholinergic Load in Women with Overactive Bladder.
Araklitis G; Robinson D; Cardozo L
Clin Interv Aging; 2020; 15():1493-1503. PubMed ID: 32921995
[TBL] [Abstract][Full Text] [Related]
7. Oxybutynin-associated Cognitive Impairment: Evidence and Implications for Overactive Bladder Treatment.
Chancellor MB; Lucioni A; Staskin D
Urology; 2024 Apr; 186():123-129. PubMed ID: 38296001
[TBL] [Abstract][Full Text] [Related]
8. SUFU white paper on overactive bladder anticholinergic medications and dementia risk.
Zillioux J; Welk B; Suskind AM; Gormley EA; Goldman HB
Neurourol Urodyn; 2022 Nov; 41(8):1928-1933. PubMed ID: 36066046
[TBL] [Abstract][Full Text] [Related]
9. Increased risk of dementia among patients with overactive bladder treated with an anticholinergic medication compared to a beta-3 agonist: a population-based cohort study.
Welk B; McArthur E
BJU Int; 2020 Jul; 126(1):183-190. PubMed ID: 32167223
[TBL] [Abstract][Full Text] [Related]
10. Anticholinergic prescription: are healthcare professionals the real burden?
Araklitis G; Thiagamoorthy G; Hunter J; Rantell A; Robinson D; Cardozo L
Int Urogynecol J; 2017 Aug; 28(8):1249-1256. PubMed ID: 28091711
[TBL] [Abstract][Full Text] [Related]
11. Treatments for overactive bladder: focus on pharmacotherapy.
Geoffrion R;
J Obstet Gynaecol Can; 2012 Nov; 34(11):1092-1101. PubMed ID: 23231848
[TBL] [Abstract][Full Text] [Related]
12. [Impact on cognitive function of anticholinergic drugs used for the treatment of overactive bladder in the elderly].
Kerdraon J; Robain G; Jeandel C; Mongiat Artus P; Gamé X; Fatton B; Scheiber-Nogueira MC; Vetel JM; Mares P; Petit AC; Amarenco G;
Prog Urol; 2014 Sep; 24(11):672-81. PubMed ID: 25214448
[TBL] [Abstract][Full Text] [Related]
13. Re: AUGS Consensus Statement: Association of Anticholinergic Medication Use and Cognition in Women with Overactive Bladder.
Wein AJ
J Urol; 2018 Sep; 200(3):503-504. PubMed ID: 30412988
[No Abstract] [Full Text] [Related]
14. Anticholinergic medications in patients admitted with cognitive impairment or falls (AMiCI). The impact of hospital admission on anticholinergic cognitive medication burden. Results of a multicentre observational study.
Weichert I; Romero-Ortuno R; Tolonen J; Soe T; Lebus C; Choudhury S; Nadarajah CV; Nanayakkara P; Orrù M; Di Somma S;
J Clin Pharm Ther; 2018 Oct; 43(5):682-694. PubMed ID: 29729025
[TBL] [Abstract][Full Text] [Related]
15. The Differential Risk of Mortality Among Users of Overactive Bladder Anticholinergic Medications and β3 Agonists.
Welk B
Eur Urol Focus; 2023 Jan; 9(1):168-171. PubMed ID: 35987891
[TBL] [Abstract][Full Text] [Related]
16. Anticholinergic drugs and risk of dementia: Time for action?
Bell B; Avery A; Bishara D; Coupland C; Ashcroft D; Orrell M
Pharmacol Res Perspect; 2021 May; 9(3):e00793. PubMed ID: 34087056
[TBL] [Abstract][Full Text] [Related]
17. Medication Profiles of Patients with Cognitive Impairment and High Anticholinergic Burden.
Green AR; Reifler LM; Boyd CM; Weffald LA; Bayliss EA
Drugs Aging; 2018 Mar; 35(3):223-232. PubMed ID: 29404965
[TBL] [Abstract][Full Text] [Related]
18. Cognitive changes in women starting anticholinergic medications for overactive bladder: a prospective study.
Iyer S; Lozo S; Botros C; Wang C; Warren A; Sand P; Tomezsko J; Botros S; Gafni-Kane A; Sasso K; Goldberg RP
Int Urogynecol J; 2020 Dec; 31(12):2653-2660. PubMed ID: 31813036
[TBL] [Abstract][Full Text] [Related]
19. Temporary cognitive impairment related to administration of newly developed anticholinergic medicines for overactive bladder: two case reports.
Shiota T; Torimoto K; Momose H; Nakamuro T; Mochizuki H; Kumamoto H; Hirayama A; Fujimoto K
BMC Res Notes; 2014 Sep; 7():672. PubMed ID: 25252702
[TBL] [Abstract][Full Text] [Related]
20. Editorial Comment: Increased risk of dementia among patients with overactive bladder treated with an anticholinergic medication compared to a beta-3 agonist: a population-based cohort study.
Moreno-Palacios J
Int Braz J Urol; 2021; 47(4):890-891. PubMed ID: 33848083
[No Abstract] [Full Text] [Related]
[Next] [New Search]
